Skip to content
Home/Companies/Biotech/Solve Therapeutics
ST

Solve Therapeutics

Biotech·US·Active·1yr hold

Solve Therapeutics is a healthcare company, headquartered in United States.

Entry
2025
Hold
1yr
Status
Active
Est. EV
–

Who owns Solve Therapeutics?

Solve Therapeutics is currently owned by Abingworth through Abingworth Bioventures 8 (2021 vintage), since 2025. Across its history, Solve Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Abingworth
Most recent investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC
2 ownership periods · full history below

Key facts

HQUnited States
SectorHealthcare

Ownership history

2 ownership periods

Active
Co-held by Abingworth and General Atlantic since 2025.
Abingworth
AbingworthActive
2025 · present · Abingworth Bioventures 8 · 2021 · Life Sciences VC
MOIC
–
General Atlantic
General AtlanticActive
present · General Atlantic core growth equity fund · 2013 · Growth
MOIC
–

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Exited 2026
BiotechUK· 2024
to
Ascend Gene & Cell Therapies
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings